Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durability of glycemic control with nateglinide versus glimepiride monotherapy in type 2 diabetes
KCT0000052Phase 4Recruiting
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Apr 2009
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of nateglinide, glimepiride in type 2 diabetes mellitus (T2DM), sponsored by Ildong Pharmaceutical Co Ltd. Started Apr 2009; status: recruiting.
02
Drugs
nateglinideglimepiride
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on KCT0000052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000052.